A newcomer on the biologics scene expressing a vision to become a global player is nothing new, but it is a bold ambition when coming from CinnaGen, an Iranian biosimilars company that is only just starting its journey in the world’s major pharma markets. 30 April 2018
Grünenthal has announced that Philip Just Larsen is to join the company chief scientific officer (CSO) and member of the corporate executive board. 30 April 2018
Obesity is a huge problem in the developed world, and it’s getting bigger.
According to the World Health Organization (WHO), people with a body mass index (BMI) above 25 are classed as overweight, and those with a BMI of 30 or above are obese. 27 April 2018
Ian Churcher, vice president of drug discovery at BenevolentAI, argues that pharma needs to embrace artificial intelligence (AI) to solve the issues which underlie the stagnation of drug discovery, in an Expert View piece. 27 April 2018
Western pharmaceutical companies do not plan to reduce their presence in the Russian market due to a recent deterioration of business climate in the country, caused by a new package of Western sanctions, according to the companies and the Russian Ministry of Health, reports The Pharma Letter’s Russian correspondent. 25 April 2018
Reda Guiha, regional president of international developed markets for Pfizer Vaccines, writes a topical Expert View piece timed to coincide with World Immunization Week. 25 April 2018
The Russian national Parliament (State Duma) plans to consider the possibility of introducing a ban on the imports of drugs from the USA and some European Union states to Russia at the beginning of the current year, according to Duma press-service. 25 April 2018
Since the inception of the biopharmaceutical age in the 1980s, the share of the market held by large molecules has risen steadily to about a fifth, and growth in the sector continues inexorably at around 7.5%. 23 April 2018
The spate of mergers and acquisitions (M&As) in the Indian pharma sector continues unabated. As foreign players continue to scout for potential Indian targets to complement their existing offerings and provide a platform for incremental growth, the bogey of drug multinational companies (MNCs) attacking India's ability to produce low-cost quality generic drugs has once again come to the fore, reports The Pharma Letter’s India correspondent. 19 April 2018
A month after US healthcare giant Johnson & Johnson announced that its chief financial officer (CFO) Dominic Caruso was to retire after 12 years in the role and Takeda's finance boss left his job with the Japanese firm, France’s biggest pharma company has said that it is losing its long-standing CFO. 19 April 2018
A huge reduction in opioid prescriptions is the most striking feature of the latest report from the IQVIA Institute for Human Data Science on medicine usage and spending in the USA. 19 April 2018
Novartis’ Vas Narasimhan, who became chief executive of the company on February 1, has now found a replacement for his previous post as head of global drug development (GDD) and chief medical officer, naming John Tsai to the position. 19 April 2018
UK pharma major GlaxoSmithKline plans to become a leading supplier of anti-HIV drugs for state needs in Russia, according to sources in the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 19 April 2018
GlaxoSmithKline today revealed is has appointed Kevin Sin as senior vice president and head of worldwide business development for pharmaceuticals research and development. 18 April 2018
The USA’s Abbott has launched a new line for the production of drugs for the treatment of infertility at the facilities of its Veropharm Russian subsidiary, in the Belgorod region. 18 April 2018
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024